Kellsye P. Fabian

Also affiliated with National Cancer Institute, Center for Cancer Research

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 20 papers. Top paper: “Overcoming hypoxia-induced functional suppression of NK cells”.

Overcoming hypoxia-induced functional suppression of NK cells

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000246

N/A

2.3DataRank · unranked

68 citations

Michelle R. Padget, Kellsye P. Fabian, Benjamin Wolfson, Fabiola Cecchi, Todd Hembrough +6 more

Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells

eLife(2020)10.7554/elife.54854

N/A

2.1DataRank · unranked

59 citations

Sarah Greene, Jay Friedman, Paúl E. Clavijo, Carter Van Waes, Kellsye P. Fabian +9 more

Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2020-001691

N/A

1.8DataRank · unranked

54 citations

Michelle R. Padget, Rika Fujii, Jeffrey Schlom, James W. Hodge, Kellsye P. Fabian

Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation

Cells(2022)10.3390/cells11233826

N/A

0.520DataRank · unranked

31 citations

Joshua T. Kowalczyk, Sandy Reynolds, James W. Hodge, Kellsye P. Fabian

The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy

Molecular Therapy — Oncolytics(2021)10.1016/j.omto.2021.10.001

N/A

0DataRank · unranked

77 citations

James W. Hodge, Kellsye P. Fabian

Combinatorial Natural Killer Cell–based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells

Cancer Research Communications(2021)10.1158/2767-9764.crc-21-0020

N/A

0DataRank · unranked

27 citations

Michelle R. Padget, Kellsye P. Fabian, Anjali Nandal, Gary L. Gallia, Marijo Bilušić +4 more

Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation

Frontiers in Immunology(2022)10.3389/fimmu.2022.993624

N/A

0DataRank · unranked

19 citations

James W. Hodge, Kellsye P. Fabian, Ginette S. Santiago-Sánchez

Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-005752

N/A

0DataRank · unranked

9 citations

Kellsye P. Fabian, Michelle R. Padget, Diana C. Lopez, Austin T.K. Hoke, Clint Allen +4 more

Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12

Cancer Immunology Immunotherapy(2023)10.1007/s00262-023-03459-7

N/A

0DataRank · unranked

7 citations

Ginette S. Santiago-Sánchez, Kellsye P. Fabian, Kristen Solocinski, Paul L. Chariou, Duane H. Hamilton +6 more

Data from Therapy of Established Tumors with Rationally Designed Multiple Agents Targeting Diverse Immune–Tumor Interactions: Engage, Expand, Enable

(2023)10.1158/2326-6066.c.6550240

N/A

0DataRank · unranked

0 citations

Anthony S. Malamas, Michelle R. Padget, Kristen Solocinski, Benjamin Wolfson, Rika Fujii +4 more

Data from Therapy of Established Tumors with Rationally Designed Multiple Agents Targeting Diverse Immune–Tumor Interactions: Engage, Expand, Enable

(2023)10.1158/2326-6066.c.6550240.v1

N/A

0DataRank · unranked

0 citations

Anthony S. Malamas, Michelle R. Padget, Kristen Solocinski, Benjamin Wolfson, Rika Fujii +4 more

A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance

Cancer Biology & Therapy(2024)10.1080/15384047.2024.2308097

N/A

0DataRank · unranked

25 citations

Kellsye P. Fabian, James W. Hodge, Ginette S. Santiago-Sánchez

Alum-anchored IL-12 combined with cytotoxic chemotherapy and immune checkpoint blockade enhanced antitumor immune responses in head and neck cancer models

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009712

N/A

0DataRank · unranked

13 citations

Ginette S. Santiago-Sánchez, Michelle R. Padget, Wiem Lassoued, Clint Allen, Sailaja Battula +3 more

Chordoma cancer stem cell subpopulation characterization may guide targeted immunotherapy approaches to reduce disease recurrence

Frontiers in Oncology(2024)10.3389/fonc.2024.1376622

N/A

0DataRank · unranked

3 citations

Kellsye P. Fabian, Michelle R. Padget, Yvette Robbins, Joshua T. Kowalczyk, Wiem Lassoued +7 more

TIME for Endometrial Cancer: Advancements and Challenges in Therapeutic Targets for the Endometrial Cancer Tumor Immune Microenvironment

Cancer Immunology Research(2025)10.1158/2326-6066.cir-25-0438

N/A

0DataRank · unranked

5 citations

Kellsye P. Fabian, Jung‐Min Lee, James W. Hodge, Margaret R. Pruitt

Combination of a novel TCR Vβ chain-directed selective T cell activator with standard of care therapy for head and neck cancer improves antitumor responses and promotes regression of checkpoint-refractory tumor models

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2025-013158

N/A

0DataRank · unranked

2 citations

Ginette S. Santiago-Sánchez, Kellsye P. Fabian, Michelle R. Padget, J Lee, Clint Allen +7 more

684 ATR inhibitor tuvusertib induces immunogenic modulation and sensitizes prostate carcinoma to natural killer cell-mediated cytotoxicity which is further enhanced by the IL-15 superagonist N-803

Regular and Young Investigator Award Abstracts(2025)10.1136/jitc-2025-sitc2025.0684

N/A

0DataRank · unranked

0 citations

Patrick Soon‐Shiong, Astrid Zimmerman, Jeffrey Schlom, James W. Hodge, Kellsye P. Fabian +1 more

Therapy of Established Tumors with Rationally Designed Multiple Agents Targeting Diverse Immune–Tumor Interactions: Engage, Expand, Enable

Cancer Immunology Research(2020)10.1158/2326-6066.cir-20-0638

N/A

0DataRank · unranked

16 citations

Anthony S. Malamas, Michelle R. Padget, Kristen Solocinski, Benjamin Wolfson, Rika Fujii +4 more

Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.01.30.926535

N/A

0DataRank · unranked

3 citations

Sarah Greene, Jay Friedman, Paúl E. Clavijo, Carter Van Waes, Kellsye P. Fabian +9 more

From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment

Frontiers in Oncology(2021)10.3389/fonc.2021.728018

N/A

0DataRank · unranked

120 citations

Benjamin Wolfson, James W. Hodge, Kellsye P. Fabian